Redesign Health is reportedly seeking a hefty sum of $250 million in its latest fundraising effort. The health-focused venture firm and startup studio has previously secured $250 million for itself and its portfolio companies, obtaining $100 million in Series B funding in March 2021, followed by $65 million in Series C funding for itself in September 2022. The allocation of this new fundraising goal has not been disclosed, as the efforts are ongoing and terms may change. Redesign declined to comment on the matter.
Headquartered in New York, Redesign Health has developed and launched over 65 healthtech companies since its establishment in 2018. Combining a VC firm and startup incubator model, the company has successfully scaled startups like MedArrive and Calibrate. Notable investors backing Redesign include General Catalyst, CVS Health Ventures, and UPMC Enterprises.
In recent years, the fundraising landscape for VC firms has experienced significant shifts. Redesign’s portfolio companies, including Calibrate, have faced challenges in securing funding amid market fluctuations. Calibrate encountered cash burn issues and customer complaints, leading to acquisition negotiations with private-equity firm Madryn Asset Management after the departure of its CEO and founder. Following layoffs in February and October 2022, Redesign announced plans to prioritize supporting existing portfolio companies moving forward.
Despite these setbacks, Redesign Health has seen growth and recognition, with its post-money valuation reaching $1.7 billion after the Series C raise. As the company continues its fundraising efforts, the healthcare industry watches closely for potential developments and impacts on the healthtech startup ecosystem.